New opioid addiction drug VK4-116 begins first human safety tests
NCT ID NCT06808932
First seen Apr 11, 2026 · Last updated May 23, 2026 · Updated 5 times
Summary
This early-stage study tests a new oral drug called VK4-116 in 48 healthy volunteers to see if it is safe and how the body handles it. Participants receive either a single dose of the drug or a placebo, and researchers monitor side effects and drug levels in the blood. The goal is to gather initial safety data before testing the drug in people with opioid use disorder.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID DEPENDENCE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altasciences Clinical Kansas
Overland Park, Kansas, 66212, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.